Transcatheter Pulmonary Valve (TPV) Devices Market: By Type (Balloon-Expanded, Self-Expanded), By Application (Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Pulmonary Regurgitation, Tetralogy of Fallot, Truncus Arteriosus, and Others), By End User (Public Sector and Private Sector) and Geography

Transcatheter Pulmonary Valve (TPV) Devices Market size was valued at USD 80.85 million in 2023 and is projected to grow at 5.6% CAGR over the forecast years to reach USD 118.4 million by 2030. The transcatheter pulmonary valve (TPV) devices market is experiencing significant growth, driven by several factors such as rising cases of several cardiovascular diseases, technological advancements, increasing demand for minimally invasive procedures, and a growing geriatric population. The rising incidences of many forms of cardiovascular diseases, such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases. CVDs are responsible for 17.9 million deaths every year, according to the reports of WHO [WHO cardiovascular diseases]. This accounts for about 32% of all deaths worldwide. Over three-quarters of these CVD deaths occur in low- and middle-income countries. Further, 17 million premature deaths—before the age of 70 years—due to noncommunicable diseases alone in 2019, 38% were because of CVDs.

Very few of the other key factors likely to drive the industry are technological advancements in valve replacement procedures. A few primary reasons that indicate its surging demand and adoption rate amongst the patient population include an increasing number of product launches that are related to transcatheter heart valve technologies. The high cost of devices and procedures, reimbursement issues, and limited long-term data are the constraints, that are hindering market growth. Growing awareness, expansion into emerging markets, focus on innovation, ambulatory TPV procedures, and remote monitoring are the recent trends and opportunities in the transcatheter pulmonary valve (TPV) devices market.

Transcatheter Pulmonary Valve (TPV) Devices Market Key Developments:

• In May 2022, VenusP-Valve™, an innovative transcatheter pulmonic valve replacement (TPVR) system developed by Venus Medtech, has gained FDA approval for compassionate use in two cases. This approval underscores its unique clinical value even before formal clinical trials.
• In March 2021, the Harmony Transcatheter Pulmonary Valve from Medtronic plc received U.S. FDA approval as the first minimally invasive therapy designed to treat patients with a specific type of congenital heart defect of the right ventricle—one of the four chambers of the heart, which makes blood travel hard from it to the lungs.